Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics, Inc. (AVTX) reported beneficial ownership positions held by three funds as of September 30, 2026: Biotechnology Value Fund, L.P. held 469,361 shares, Biotechnology Value Fund II, L.P. held 353,075 shares, and Biotechnology Value Trading Fund OS LP held 65,625 shares. Their affiliated entities and manager reported shared voting and dispositive power over related positions.
BVF Partners L.P., BVF Inc. and Mark N. Lampert, a director and officer of BVF Inc., each may be deemed to beneficially own 907,406 shares, or approximately 1.7% of the class; BVF GP Holdings LLC may be deemed to own 822,436 shares, or approximately 1.5%. The 907,406-share figure includes 19,345 shares in a Partners Managed Account. The ownership figures overlap through affiliated parties. Percentages are based on 53,629,989 shares outstanding as of August 3, 2026.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen reported beneficial ownership of 1,625,019 Avalo Therapeutics, Inc. (AVTX) common shares, or 3.0% of the class, as of September 30, 2026. Each reported shared voting and dispositive power over that amount and stated that they directly owned no Avalo shares. Point72 Asset Management said it maintains investment and voting power over shares held by an investment fund it manages; Point72 Capital Advisors is its general partner, and Cohen controls both entities.
Avalo Therapeutics, Inc. (AVTX) is the issuer in a Schedule 13G reporting 3,974,000 shares, or 7.4% of the class, beneficially owned by Farallon Capital Management, L.L.C. and its managing or senior managing members: Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Varun N. Gehani, Nicolas Giauque, Avner A. Husen, David T. Kim, Michael G. Linn, Patrick (Cheng) Luo, Thomas G. Roberts, Jr., Edric C. Saito, Daniel S. Short, Andrew J. M. Spokes, John R. Warren and Mark C. Wehrly. The reported event date is September 30, 2026.
The shares are held directly by eight Farallon investment partnerships, with Farallon Capital Management serving as their investment manager. The reporting persons report shared voting and dispositive power, and the Farallon Funds have the right to receive dividends and sale proceeds.
Avalo Therapeutics, Inc. (AVTX) common stock was the subject of a Schedule 13G in which State Street Corporation reported beneficial ownership of 2,563,226 shares, equal to 4.8% of the class, with an event date of September 30, 2026. State Street reported shared voting power over 2,490,708 shares and shared dispositive power over 2,563,226 shares, with no sole voting or dispositive power. The Schedule 13G identifies SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd. as subsidiaries.
Avalо Therapeutics, Inc. (AVTX) common stock ownership reported by FMR LLC is 474,359 shares, or 0.9% of the class; Abigail P. Johnson is also listed with beneficial ownership of 474,359 shares. FMR LLC reports sole voting power over 474,127 shares and sole dispositive power over 474,359 shares. Abigail P. Johnson reports 0 shares of sole or shared voting power and sole dispositive power over 474,359 shares. Other persons have rights to dividends or sale proceeds, but no other person's interest is more than 5% of outstanding common stock.
Avalо Therapeutics, Inc. (AVTX) is the issuer whose common stock is covered in Amendment No. 5 to a beneficial-ownership report. FMR LLC and Abigail P. Johnson are each listed as beneficially owning 5,250,181 shares, or 9.8% of the class. FMR LLC reports sole voting power over 5,250,133 shares and sole dispositive power over 5,250,181 shares; Abigail P. Johnson reports no voting power and sole dispositive power over 5,250,181 shares. One or more other persons have rights to dividends or sale proceeds, but no other person's interest exceeds 5% of outstanding common stock.
Avalo Therapeutics, Inc. entered into an at-the-market sales agreement with Jefferies LLC under which it may issue and sell common shares with an aggregate offering price of up to $200,000,000. Avalo is not obligated to sell shares, and Jefferies is not required to sell any specific number or dollar amount. Avalo will pay Jefferies a commission of up to 3.0% of gross proceeds from shares sold through the agent.
Avalo’s prior sales agreement with TD Securities (USA) LLC was terminated effective immediately on November 5, 2026. No additional shares may be sold under that agreement or its related prospectus supplement.
Avalo Therapeutics, Inc. filed an automatic shelf registration covering common stock, preferred stock, debt securities, warrants and/or units. Avalo and/or selling stockholders may offer securities from time to time after effectiveness, with specific terms and amounts described in a prospectus supplement. Avalo says it will receive no proceeds from selling-stockholder sales; net proceeds from its own sales are intended for general corporate purposes, including clinical trials, research and development, and general and administrative expenses, unless a supplement states otherwise.
Avalo describes abdakibart as advancing into a Phase 3 registrational program for hidradenitis suppurativa and reports that Phase 2 LOTUS met its primary endpoint at both tested doses. The prospectus states 42.2% and 42.9% absolute improvement in HiSCR75 response rates at Week 16 for 150 mg and 300 mg, respectively, and 42.5% combined, versus a 25.6% placebo rate.
Avalo Therapeutics, Inc. (AVTX) may offer and sell common stock with an aggregate offering price of up to $200,000,000 from time to time through Jefferies under an at-the-market sales agreement; sales may also occur in negotiated transactions, including block trades. Jefferies is not required to sell a specific amount and may receive a commission of up to 3.0% of gross proceeds from shares it sells.
Avalo intends to use net proceeds, if any, primarily for ongoing clinical development of abdakibart and AVTX-010, working capital and other general corporate purposes. Common shares outstanding were 53,923,083 as of September 30, 2026. The offering illustration assumes a sale of 27,322,404 shares at $7.32 per share, the last reported sale price on November 2, 2026, and lists up to 81,245,487 shares outstanding immediately after the offering, assuming no options or warrants are exercised, preferred stock is converted, or restricted or performance stock units vest. Avalo also reports that Phase 2 LOTUS met its primary endpoint, citing a 42.5% combined absolute improvement in HiSCR75 response at Week 16 and a 25.6% placebo rate.
Avalo Therapeutics, Inc. reported a third-quarter 2026 net loss of $18.9 million, compared with $30.6 million in the third quarter of 2025; basic and diluted net loss per share was $0.34 versus $2.19. Operating expenses totaled $23.4 million, up from $19.2 million, including research and development expense of $15.0 million (up $1.4 million) and general and administrative expense of $8.4 million (up $2.8 million). Avalo attributed the lower net loss mainly to the change in fair value related to its derivative liability, which more than offset the $4.2 million increase in operating expenses.
Cash, cash equivalents and investments were $462.8 million as of September 30, 2026, and Avalo expects these resources to fund operations into 2029; net cash used in operating activities was $49.2 million for the nine months ended September 30, 2026. Avalo plans to initiate a registrational Phase 3 program for abdakibart in hidradenitis suppurativa in the first half of 2027 and anticipates an Investigational New Drug submission for AVTX-010 in the first half of 2027.